போது க்ளேண்மர்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Glenmark, Menarini ink licensing pact for Ryaltris Nasal Spray in European market
medicaldialogues.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicaldialogues.in Daily Mail and Mail on Sunday newspapers.
Glenmark and Menarini enter into exclusive agreement
afghanistannews.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from afghanistannews.net Daily Mail and Mail on Sunday newspapers.
Glenmark Pharmaceuticals and Menarini enter into Exclusive Licensing Agreement for commercializing Ryaltris™ Nasal Spray
Posted On: 2020-12-22 20:36:41 (Time Zone: Arizona, USA)
Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led global integrated pharmaceutical company, today announced that its Swiss subsidiary, Glenmark Specialty S.A., has entered into an exclusive licensing agreement with Menarini Group (Menarini) for commercializing its innovative nasal spray Ryaltris™ across 33 countries in Europe, including the Balkan region.
Ryaltris™ [olopatadine hydrochloride (665 mcg) and mometasone furoate (25 mcg)], developed by Glenmark, is a novel fixed-dose combination nasal spray of an anti-histamine and a steroid, indicated for treatment of symptoms associated with seasonal allergic rhinitis (SAR) in patients over 12 years of age.
Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals and Menarini enter into exclusive licensing agreement for commercializing Ryaltris™ nasal spray across numerous markets throughout Europe ANI | Updated: Dec 23, 2020 11:14 IST
Mumbai (Maharashtra) [India] December 23 (ANI/PRNewswire): Glenmark Pharmaceuticals Ltd (Glenmark), a research-led global integrated pharmaceutical company, today announced that its Swiss subsidiary, Glenmark Specialty SA, has entered into an exclusive licensing agreement with Menarini Group (Menarini) for commercializing its innovative nasal sprayRyaltris™ across 33 countries in Europe, including the Balkan region.
Ryaltris™ [olopatadine hydrochloride (665 mcg) and mometasone furoate (25 mcg)], developed by Glenmark, is a novel fixed-dose combination nasal spray of an anti-histamine and a steroid, indicated for the treatment of symptoms associated with seasonal allergic rhinitis (SAR) in patients over 12 year
Glenmark to commercialize Ryaltris⢠nasal spray throughout Europe
Glenmark to commercialize Ryaltris⢠nasal spray throughout Europe
23 December 2020 | News
Source credit: Shutterstock
Glenmark Pharmaceuticals Ltd, a research-led global integrated pharmaceutical company, has announced that its Swiss subsidiary, Glenmark Specialty SA, has entered into an exclusive licensing agreement with Menarini Group (Menarini) for commercialising its innovative nasal spray Ryaltris™ across 33 countries in Europe, including the Balkan region.
Ryaltris™ [olopatadine hydrochloride (665 mcg) and mometasone furoate (25 mcg)], developed by Glenmark, is a novel fixed-dose combination nasal spray of an anti-histamine and a steroid, indicated for treatment of symptoms associated with seasonal allergic rhinitis (SAR) in patients over 12 years of age.
vimarsana © 2020. All Rights Reserved.